Jan 25 (Reuters) - Merck is no longer in discussions to buy cancer drug developer Revolution Medicines, the Wall Street ...

Merck & Co., Inc. (NYSE:MRK) is included among the 15 Best S&P 500 Dividend Stocks to Buy in 2026. On January 20, TD Cowen ...

Investors are apparently taking bets on when Revolution will be acquired. A handful of pharmas could be interested as Merck ...

The pharmaceutical giant had been in talks to buy the cancer drug developer in a transaction that could have valued ...

Bristol Myers Squibb, GSK and Merck are contributing drug ingredients as part of their deals with the White House but are ...

US pharma major Merck (NYSE: MRK) has ended discussions to acquire Revolution Medicines (Nasdaq: RVMD) after the two sides failed to align on price, cooling a process that had briefly dangled a ...

Venture investors are adopting a more aggressive mindset heading into 2026, while Merck, Moderna and Summit are all ...

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...

Merck & Co. Inc. (NYSE:MRK) ranks among the most active blue chip stocks to buy now. With a raised price target of $130 per ...

By Kamal Choudhury and Mariam Sunny Jan 20 (Reuters) - Moderna and Merck said on Tuesday their experimental personalized ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $113.3, a high estimate of $130.00, and a low estimate of $95.00. This current ...

The drugmaker had recently been in discussions to acquire RevMed in a deal that could have valued the cancer-drug biotech at ...